Page 11 - Confidence Interval News Today

1. In this randomized crossover trial, intravenous levothyroxine, given to hemodynamically unstable brain-dead potential heart donors, did not improve the heart transplant success rates compared to placebo. 2. Levothyroxine resulted in more severe hypertension and tachycardia as compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: The majority of transplanted hearts come from brain-dead

1. In this matched cohort study, approximately one in three patients who had transient new-onset atrial fibrillation (AF) during hospitalization had recurrent AF within one year. 2. Most study patients with recurrent AF were detected by electrocardiogram (ECG) patch monitor only. Evidence Rating Level: 1 (Excellent) Study Rundown: AF is a common arrhythmia associated with

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

– ZUMA-1 Post-Hoc Analysis Shows Five-Year Lymphoma-Related Event-Free Survival in a Substantial Proportion of Patients with Refractory Large B-cell Lymphoma – – Four-Year Follow-up from...

– First Ever Prospective Phase 2 Study to Evaluate CAR T-Cell Therapy as First-Line Therapy Reads Out Three-Year Follow-Up Analysis – – At Median Follow-Up of 40.9 Months, Patients Treated...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

1. In this cross-sectional study, having carrier status of actionable genes identified by the American College of Medical Genetics and Genomics (ACMG) was associated with reduced life span compared to non-carrier status. 2. Having carrier status for an actionable cancer gene was associated with a shorter life span by an average of three years compared

1. In this retrospective cohort study, five risk factors (body mass index, systolic blood pressure, non–high-density lipoprotein cholesterol, current smoking, and diabetes) contributed to increased incidence of cardiovascular disease. 2. These factors were also noted to increase the risk of death from any cause. Evidence Rating Level: 2 (Good) Study Rundown: Modifiable risk factors such

New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® compared to epoetin alfa ...

New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of response with Reblozyl® (luspatercept-aamt) compared to epoetin alfaPRINCETON, N.J.--(BUSINESS WIRE)--$BMY #ASH--Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary...